NFE2L2 and Miyoshi myopathy: DCG066, a novel methyltransferase inhibitor, induces ferroptosis in MM by reducing SLC7A11, GPX4, NRF2, and HO-1 expression, with its effects reversible by ferroptosis inhibitors and the NRF2 activator tert-butyl hydroquinone (TBHQ) [168].